CTNNB1 and neoplasm: In the β-M model, treatment was ceased at 8 weeks, yet by ~16.5 weeks post-LNP-CTNNB1 treatment, gross tumor burden was equivalent to that observed with LNP-CTRL treatment at the ~7.5 weeks which had been lethal in β-M mice (Figure S5e–f).